Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) and Kytopen have announced a partnership to enhance cell therapy manufacturing through integrated cellular engineering workflow. The collaboration combines Bio-Techne's TcBuster™ GMP non-viral genome engineering system with Kytopen's Flowfect Tx™ GMP cellular engineering platform.
The TcBuster™ system enables simultaneous delivery of multiple genes with high editing efficiency in a single vector, while Flowfect® technology processes billions of cells in minutes using a combination of mechanical, electrical, and chemical forces. Together, these technologies aim to streamline gene delivery processes and accelerate the development of advanced cell therapies.
The companies will present their collaborative data at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting in New Orleans, May 7-10, 2025.
Positive
- Integration of TcBuster and Flowfect technologies enables processing of billions of cells in minutes
- TcBuster system allows delivery of multiple genes simultaneously with high editing efficiency
- Combined technologies offer streamlined non-viral gene delivery process for faster therapeutic doses
- Platform suitable for various immune cell types, particularly non-dividing and apoptosis-sensitive cells
Negative
- None.
News Market Reaction
On the day this news was published, TECH gained 2.11%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing.
- The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes.
- The companies' combined technologies deliver high gene insertion efficiencies and high cell viabilities, enabling a non-viral gene-editing workflow ideal for the development of advanced cell therapies.
- The data will be presented in a poster at ISCT, May 7-10, 2025, in
New Orleans .
Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods. The hyperactive TcBuster transposase enables delivery of multiple genes simultaneously while maintaining high editing efficiency and a de-risked insertional profile. Flowfect® technology is a highly tunable system. It is unique in that it combines mechanical, electrical, and chemical forces, and allows the adjustment of multiple parameters to maximize transfection efficiency, cell health, and cell yield, while continuous flow enables the processing of hundreds of billions of healthy, high-quality engineered cells in just minutes. Together these technologies provide a streamlined gene delivery process that can achieve therapeutic doses quicker.
"We are excited about the opportunity to work with such a reputable life science provider as Bio-Techne", said Kevin Gutshall, Chief Commercial Officer at Kytopen, "Together our technologies offer a non-viral, gene-editing platform suitable for a range of immune cell types, in particular non-dividing cells and those sensitive to apoptosis, that will enable developers to bring more effective, advanced cell therapies to market quicker."
Data generated through the collaboration will be presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting, May 7-10, 2025, in
ISCT Poster Presentation. Wednesday, May 7, 2025, at 6:00pm; POSTER BOARD: 1105
CONTINUOUS FLOW TRANSFECTION WITH FLOWFECT® TECHNOLOGY AS AN EFFICIENT, NON-VIRAL TECHNOLOGY FOR SCALABLE CRISPR-MEDIATED ENGINEERING OF PRIMARY T CELLS
Global Showcase. 15 min Presentation, Thursday, May 8, 2025, at 6:00pm
A FULLY VALIDATED, NON-VIRAL GMP PLATFORM FOR THE MANUFACTURE OF ENGINEERED CELLS AT CLINICAL AND COMMERCIAL SCALE
For further information:
Kytopen:
Investor Contact:
Michael Chiu PhD., CEO
mchiu@kytopen.com
Business and Corporate Development Contact:
Kevin Gutshall, CCO
kgutshall@kytopen.com
About Kytopen:
The innovative leader in non-viral, continuous flow cellular engineering technologies, Kytopen, headquartered in
Bio-Techne
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
View original content to download multimedia:https://www.prnewswire.com/news-releases/kytopen-and-bio-techne-collaborate-on-an-integrated-cellular-engineering-workflow-to-expedite-cell-therapy-manufacturing-302449438.html
SOURCE Kytopen
FAQ
What is the partnership between Bio-Techne (TECH) and Kytopen focused on?
What are the key benefits of Bio-Techne's TcBuster system for cell therapy?
How does Kytopen's Flowfect technology enhance cell therapy manufacturing?
When and where will Bio-Techne and Kytopen present their collaboration data?
